The treatment of prostate cancer (PC) has evolved significantly over the years—surgical techniques, chemotherapy, abundant forms of radiotherapy, androgen receptor signaling inhibitors (ARSIs), agonists and antagonists of luteinizing hormone-releasing hormone (LHRH), and poly (ADP-ribose) polymerase inhibitors (PARPi) represent the treatment landscape of PC. This evidence concerns the gene GNRH1 and pachyonychia congenita.